Seamus Fernandez's Stock Ratings

Guggenheim Analyst

Seamus Fernandez is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

16.7%

Smart Score

69.8%

Overall Average Return Percentile

73rd

Number of Ratings

30
Buy NowGet Alert
04/29/2024ALTBuy Now
Altimmune
$7.69——DowngradeBuy → NeutralGet Alert
03/05/2024APGEBuy Now
Apogee Therapeutics
$52.4273.6%$44 → $91MaintainsBuyGet Alert
03/04/2024GSKBuy Now
GSK
$44.63——UpgradeNeutral → BuyGet Alert
01/03/2024APGEBuy Now
Apogee Therapeutics
$52.42-16.06%$29 → $44MaintainsBuyGet Alert
01/02/2024ICVXBuy Now
Icosavax
———DowngradeBuy → NeutralGet Alert
11/17/2023ICVXBuy Now
Icosavax
—— → $28Initiates → BuyGet Alert
11/15/2023HLVXBuy Now
HilleVax
$14.40136.11%$38 → $34MaintainsBuyGet Alert
08/15/2023VERVBuy Now
Verve Therapeutics
$5.90832.2%$56 → $55MaintainsBuyGet Alert
08/11/2023CBAYBuy Now
CymaBay Therapeutics
—— → $20Initiates → BuyGet Alert
08/08/2023APGEBuy Now
Apogee Therapeutics
$52.42-44.68% → $29Initiates → BuyGet Alert
07/14/2023ARCTBuy Now
Arcturus Therapeutics
$30.49——MaintainsBuyGet Alert
04/11/2023MRKBuy Now
Merck & Co
$131.32-5.57%$123 → $124MaintainsBuyGet Alert
04/11/2023LLYBuy Now
Eli Lilly
$806.66-51.4%$395 → $392MaintainsBuyGet Alert
03/29/2023ARCTBuy Now
Arcturus Therapeutics
$30.4918.07% → $36Reiterates → BuyGet Alert
03/07/2023MLYSBuy Now
Mineralys Therapeutics
$12.81149.8% → $32Initiates → BuyGet Alert
02/28/2023PCVXBuy Now
Vaxcyte
$74.02-12.19%$66 → $65MaintainsBuyGet Alert
02/28/2023GPCRBuy Now
Structure Therapeutics
$36.2238.06% → $50Initiates → BuyGet Alert
01/11/2023ALBOBuy Now
Albireo Pharma
———DowngradeBuy → NeutralGet Alert
12/15/2022PCVXBuy Now
Vaxcyte
$74.02-10.83% → $66Initiates → BuyGet Alert
12/07/2022LLYBuy Now
Eli Lilly
$806.66-50.29%$399 → $401MaintainsBuyGet Alert
11/15/2022DICEBuy Now
DICE Therapeutics
—— → $65Initiates → BuyGet Alert
11/01/2022MRKBuy Now
Merck & Co
$131.32-15.47%$104 → $111MaintainsBuyGet Alert
10/10/2022MRKBuy Now
Merck & Co
$131.32——UpgradeNeutral → BuyGet Alert
10/10/2022BMYBuy Now
Bristol-Myers Squibb
$42.49——DowngradeBuy → NeutralGet Alert
09/16/2022ALTBuy Now
Altimmune
$7.69237.99%$31 → $26MaintainsBuyGet Alert
09/08/2022ALBOBuy Now
Albireo Pharma
—— → $55Initiates → BuyGet Alert
05/31/2022NVOBuy Now
Novo Nordisk
$134.55——UpgradeNeutral → BuyGet Alert
05/24/2022HLVXBuy Now
HilleVax
$14.40177.78% → $40Initiates → BuyGet Alert
12/15/2021ADGIBuy Now
Adagio Therapeutics
———DowngradeBuy → NeutralGet Alert
12/07/2021MRKBuy Now
Merck & Co
$131.32——DowngradeBuy → NeutralGet Alert

Recent Analyst Stock Rating News

Arcturus Therapeutics Stock Is Rising Wednesday: What's Going On?
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares are trading higher Wednesday after the company reported strong fourth-quarter results and provided an update on pipeline progress.
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim. The Analyst: Seamus Fernandez upgraded the rating for Merck from Neutral to Buy, while establishing a price target of $104.
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo.
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Tesaro Shares Lower On Receipt Of FDA Complete Response Letter
Why The Amgen/Regeneron Patent Saga Is Far From Over
Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target
Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free